Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 7.8% - Time to Sell?

Key Points

• Oruka Therapeutics shares fell about 7.8% to $31.72 midday, trading just 68,378 shares (≈83% below average volume) and sitting below its 50‑day moving average of $32.65.
• Analyst sentiment is largely positive—eight Buy ratings versus one Sell—with a consensus rating of Moderate Buy and a consensus price target of $54.50, though individual targets range from $45 to $75 and Weiss Ratings maintains a sell.
• Insiders have been net sellers (21,000 shares sold in the last 90 days; Joana Goncalves sold 7,000), insiders own ~24.7% and institutions ~56.4%, while the company remains a clinical‑stage biotech (market cap ≈$1.58B) with lead candidate ONCT‑01 in Phase 1.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) fell 7.8% during mid-day trading on Thursday . The stock traded as low as $31.75 and last traded at $31.7220. 68,378 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 414,029 shares. The stock had previously closed at $34.41.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wedbush raised their price target on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an "outperform" rating in a research report on Tuesday, January 13th. Piper Sandler assumed coverage on shares of Oruka Therapeutics in a research report on Thursday, December 18th. They issued an "overweight" rating and a $75.00 price objective for the company. BTIG Research increased their price objective on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, January 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Finally, UBS Group began coverage on Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $50.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.50.

Oruka Therapeutics Stock Down 4.9%

The company's 50-day moving average is $32.65 and its two-hundred day moving average is $27.29. The company has a market cap of $1.58 billion, a P/E ratio of -17.21 and a beta of -0.38.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the transaction, the insider directly owned 34,018 shares of the company's stock, valued at $1,101,162.66. This represents a 17.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 21,000 shares of company stock worth $663,530. 24.69% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC raised its stake in shares of Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock valued at $1,476,000 after buying an additional 420 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock valued at $92,000 after buying an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company's stock valued at $71,000 after buying an additional 904 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter worth $37,000. Institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.